Cited Literature
Return to HTAJ Home Page
Return to Title/Abstract/Chapter Table of Contents
Return to Chapter 7: Editorial Conclusions
1. Salmon SE, Hamburger AW, Soehnlen B, Durie BG, Alberts DS, Moon TE.
Quantitation of differential sensitivity of human-tumor stem cells to anticancer
drugs. N Engl J Med 1978; 298: 1321-1327.
2. Von Hoff DD, Casper J, Bradley E, Sandbach J, Jones D, Makuch R. Association
between human tumor colony-forming assay results and response to an individual
patient's tumor to chemotherapy. Am J Med 1981; 70: 1027-1032.
3. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis
Rev 1992; 11: 121-139.
4. Zunino F, Perego P, Pilotti S, Pratesi G, Supino R, Arcamone F. Role
of apoptotic response in cellular resistance to cytotoxic agents. Pharmacol
Ther 1997; 76: 177-185.
5. Jaffrezou JP, Bettaieb A, Levade T, Laurent G. Antitumor agent-induced
apoptosis in myeloid leukemia cells: a controlled suicide. Leuk Lymphoma
1998; 29: 453-463.
6. Selby P, Buick RN, Tannock I. A critical appraisal of the "human
tumor stem cell assay". New Engl J Med 1983; 308: 129-134.
7. Lieber MM, Kovach JS. Soft agar colony formation assay for chemotherapeutic
sensitivity of human solid tumors. Mayo Clin Proc 1982; 57: 527-528.
8. Tanigawa N, Kern DH, Kikasa Y, Morton DL. Rapid assay for evaluating
the chemosensitivity of human tumors in soft agar culture. Cancer Res 1982;
42: 2159-2164.
9. Kern DH, Weisenthal LM. Highly specific prediction of antineoplastic
drug resistance with an in vitro assay using suprapharmacologic drug exposures.
J Natl Cancer Inst 1990; 82: 582-588.
10. Weisenthal LM, Kern DH. Prediction of drug resistance in cancer chemotherapy:
the Kern and DISC assays. Oncology (U S A ) 1992; 5: 93-103;.
11. Fernandez-Trigo V, Shamsa F, Vidal-Jove J, Kern DH, Sugarbaker PH.
Prognostic implications of chemoresistance-sensitivity assays for colorectal
and appendiceal cancer. Am J Clin Oncol 1995; 18: 454-460.
12. Eltabbakh GH, Piver MS, Hempling RE, et al. Correlation between extreme
drug resistance assay and response to primary paclitaxel and cisplatin
in patients with epithelial ovarian cancer. Gynecol Oncol 1998; 70: 392-397.
13. Eltabbakh GH. Extreme drug resistance assay and response to chemotherapy
in patients with primary peritoneal carcinoma. J Surg Oncol 2000; 73: 148-152.
14. Ajani JA, Baker FL, Spitzer G, et al. Comparison between clinical response
and in vitro drug sensitivity of primary human tumors in the adhesive tumor
cell culture system. J Clin Oncol 1987;
5: 1912-1921.
15. Weisenthal LM, Shoemaker RH, Marsden JA, Dill PL, Baker JA, Moran EM.
In vitro chemosensitivity assay based on the concept of total tumor cell
kill. Recent Results Cancer Res 1984; 94: 161-173.
16. Weisenthal LM, Lippman ME. Clonogenic and nonclonogenic in vitro chemosensitivity
assays. Cancer Treat Rep 1985; 69: 615-632.
17. Weisenthal LM. Cell culture assays for hematologic neoplasms based
on the concept of total tumor cell kill. In: Kaspers GJL, Pieters R, Twentyman
PR, Weisenthal LM, Veerman AJP, eds. Drug Resistance in Leukemia and Lymphoma.
Langhorne, PA: Harwood Academic Publishers, 1993: 415-432.
18. Weisenthal LM. Clinical correlations for cell culture assays based
on the concept of total tumor cell kill. Contrib Gynecol Obstet 1994; 19:
82-90.
19. Weisenthal LM, Marsden JA, Dill PL, Macaluso CK. A novel dye exclusion
method for testing in vitro chemosensitivity of human tumors. Cancer Res
1983; 43: 749-757.
20. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation
of a tetrazolium-based semiautomatic colorimetric assay: assessment of
chemosensitivity testing. Cancer Res 1987; 47: 936-942.
21. Kangas L, Gronroos M, Nieminen AL. Bioluminescence of cellular ATP:
a new method for evaluating cytotoxic agents in vitro. Med Biol 1984; 62:
338-343.
22. Garewal HS, Ahmann FR, Schifman RB, Celniker A. ATP assay: ability
to distinguish cytostatic from cytocidal anticancer drug effects. J Natl
Cancer Inst 1986; 77: 1039-1045.
23. Sevin B-U, Peng ZL, Perras JP, Ganjei P, Penalver M, Averette HE. Application
of an ATP-bioluminescence assay in human tumor chemosensitivity testing.
Gynecol Oncol 1988; 31: 191-204.
24. Rotman B, Teplitz C, Dickinson K, Cozzolino JP. Individual human tumors
in short-term micro-organ cultures: Chemosensitivity testing by fluorescent
cytoprinting. In Vitro Cell Dev Biol 1988; 24: 1137-1138.
25. Larsson R, Nygren P, Ekberg M, Slater L. Chemotherapeutic drug sensitivity
testing of human leukemia cells in vitro using a semiautomated fluorometric
assay. Leukemia 1990; 4: 567-571.
26. Nygren P, Kristensen J, Jonsson B, et al. Feasibility of the fluorometric
microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing
of tumor cells from patients with acute lymphoblastic leukemia. Leukemia
1992; 6: 1121-1128.
27. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation
of a tetrazolium-based semiautomatic colorimetric assay: assessment of
radiosensitivity. Cancer Res 1987; 47: 943-946.
28. Twentyman PR, Fox NE, Rees JKH. Chemosensitivity testing of fresh leukaemia
cells using the MTT colorimetric assay. Br J Haematol 1989; 71: 19-24.
29. Pieters R, Huismans DR, Leyva A, Veerman AJP. Comparison of the rapid
automated MTT-assay with a dye exclusion assay for chemosensitivity testing
in childhood leukaemia. Br J Cancer 1989; 59: 217-220.
30. Pieters R, Huismans DR, Leyva A, Veerman AJP. Sensitivity to purine
analogues in childhood leukemia assessed by the automated MTT-assay. Adv
Exp Med Biol 1989; 253A: 447-454.
31. Kirkpatrick DL, Duke M, Goh TS. Chemosensitivity testing of fresh human
leukemia cells using both a dye exclusion assay and a tetrazolium dye (MTT)
assay. Leuk Res 1990; 14: 459-466.
32. Tsai CM, Ihde DC, Kadoyama C, Venzon D, Gazdar AF. Correlation of in
vitro drug sensitivity testing of long-term small cell lung cancer cell
lines with response and survival. Eur J Cancer 1990; 26: 1148-1152.
33. Dmitrovsky E, Seifter EJ, Gazdar AF, et al. A phase II trial of carboplatin
(CBDCA) in small-cell and non-small-cell lung cancer with correlation to
in vitro analysis of cytotoxicity. Am J Clin Oncol 1990; 13: 285-289.
34. Hanson JA, Bentley DP, Bean EA, Nute SR, Moore JL. In vitro chemosensitivity
testing in chronic lymphocytic leukaemia patients. Leuk Res 1991; 15: 565-569.
35. Rhedin AS, Tidefelt U, J”nsson K, Lundin A, Paul C. Comparison of a
bioluminescence assay with differential staining cytotoxicity for cytostatic
drug testing in vitro in human leukemic cells. Leuk Res 1993; 17: 271-276.
36. Nygren P, Hagberg H, Glimelius B, et al. In vitro drug sensitivity
testing of tumor cells from patients with non-Hodgkin's lymphoma using
the fluorometric microculture cytotoxicity assay. Ann Oncol 1994; 5 Suppl
1: S127-S131.
37. Leone LA, Meitner PA, Myers TJ, et al. Predictive value of the fluorescent
cytoprint assay (FCA): A retrospective correlation study of in vitro chemosensitivity
and individual responses to chemotherapy. Cancer Invest 1991; 9: 491-503.
38. Beksac M, Kansu E, Kars A, Ibrahimoglu Z, Firat D. A rapid drug sensitivity
assay for neoplasmatic cells. Med Oncol Tumor Pharmacother 1988; 5: 253-257.
39. Bosanquet AG. Correlations between therapeutic response of leukaemias
and in-vitro drug-sensitivity assay. Lancet 1991; 337: 711-716.
40. Hongo T, Fujii Y, Igarashi Y. An in vitro chemosensitivity test for
the screening of anti-cancer drugs in childhood leukemia. Cancer 1990;
65: 1263-1272.
41. Hongo T, Fujii Y, Yajima S. In vitro chemosensitivity of childhood
leukemic cells and the clinical value of assay directed chemotherapy. In:
Kaspers GJL, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP, eds.
Drug resistance in leukemia and lymphoma. Langhorne, PA: Harwood Academic
Publishers, 1993: 319.
42. Kaspers GJL, Pieters R, Van Zantwijk CH, De Waal FC, Van Wering ER,
Veerman AJP. Is resistance to prednisolone in vitro related to the response
to predniso(lo)ne in vivo at initial diagnosis in childhood acute lymphoblastic
leukemia? - a preliminary analysis. In: Kaspers GJL, Pieters R, Twentyman
PR, Weisenthal LM, Veerman AJP, eds. Drug Resistance in Leukemia and Lymphoma.
Chur: Harwood Academic Publishers, 1993: 321-328.
43. Larsson R, Kristensen J, Sandberg C, Nygren P. Laboratory determination
of chemotherapeutic drug resistance in tumor cells from patients with leukemia,
using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer
1992; 50: 177-185.
44. Lathan B, von Tettau M, Verpoort K, Diehl V. Pretherapeutic drug testing
in acute leukemias for prediction of individual prognosis. Haematol Blood
Transfus 1990; 33: 295-298.
45. Weisenthal LM, Dill PL, Finklestein JZ, Duarte TE, Baker JA, Moran
EM. Laboratory detection of primary and acquired drug resistance in human
lymphatic neoplasms. Cancer Treat Rep 1986; 70: 1283-1295.
46. Langkjer ST, Norgaard JM. Use of the MTT-assay for evaluation of chemosensitivity
in adult acute myeloid leukemia. In: Kaspers GJ, Pieters R, Twentyman PR,
Weisenthal LM, Veerman AJP, eds. Drug Resistance in Leukemia and Lymphoma.
Chur: Harwood Academic Publishers, 1993: 279-291.
47. Staib P, Lathan B, Schinkothe T, et al. . Prognosis in Adult AML is
precisely predicted by the DISC-assay using the chemosensitivity-index
C1. Adv Exper Med Biol 1999; 457: 437-444.
48. Santini V, Bernabei PA, Dal Pozzo O, Santini S, Rossi Ferrini P. Acute
myeloid leukemia (AML) sensitivity to antiblastics is predictable by INT
assay. In: Kaspers GJ, Pieters R, Twentyman PR, Weisenthal LM, Veerman
AJP, eds. Drug Resistance in Leukemia and Lymphoma. Chur: Harwood Academic
Publishers, 1993: 365-368.
49. Sargent JM, Taylor CG. Appraisal of the MTT assay as a rapid test of
chemosensitivity in acute myeloid leukaemia. Br J Cancer 1989; 60: 206-10.
50. Stute N, Kohler T, Lehmann L. Drug resistance testing in acute myeloid
leukemia. Adv Exper Med Biol 1999; 457: 445-452.
51. Larsson R, Jonsson B, Kristensen J, et al. Drug sensitivity testing
of tumor cells from patients with acute leukemia and non-Hodgkin's lymphoma
using a fluorometric microculture cytotoxicity assay. In: Kaspers GJL,
Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP, eds. Drug Resistance
in Leukemia and Lymphoma. Chur: Harwood Academic Publishers, 1993: 399-407.
52. Santini V, Bernabei PA, Silvestro L, et al. In vitro chemosensitivity
testing of leukemic cells: prediction of response to chemotherapy in patients
with acute non-lymphocytic leukemia. Hematol Oncol 1989; 7: 287-93.
53. Tidefelt U, Sundman-Engberg B, Rhedin AS, Paul C. In vitro drug testing
in patients with acute leukemia with incubations mimicking in vivo intracellular
drug concentrations. Eur J Haematol 1989; 43: 374-384.
54. Blackman KE, Fingert HJ, Fuller AF, Meitner PA. The Fluorescent Cytoprint
Assay in gynecologic malignancies and breast cancer: methodology and results.
In: Koechli OR, Sevin B-U, Haller U, eds. Chemosensitivity testing in gynecologic
malignancies and breast cancer. Basel: Karger, 1994: 53-64.
55. Cree IA, Kurbacher CM, Untch M, et al. Correlation of the clinical
response to chemotherapy in breast cancer with ex vivo chemosensitivity.
Anticancer Drugs 1996; 7: 630-635.
56. Koechli OR, Avner BP, Sevin B-U, et al. Application of the adenosine
triphosphate-cell viability assay in human breast cancer chemosensitivity
testing: a report on the first results. J Surg Oncol 1993; 54: 119-125.
57. Xu J-M, Song S-T, Tang Z-M, et al. . Predictive chemotherapy of advanced
breast cancer directed by MTT assay in vitro. Breast Cancer Res Treat 1999;
53: 77-85.
58. Bosanquet AG, Copplestone JA, Johnson SA, et al. Response to cladribine
in previously treated patients with chronic lymphocytic leukaemia identified
by ex vivo assessment of drug sensitivity by DiSC assay. Br J Haematol
1999; 106: 474-476.
59. Silber R, Degar B, Costin D, et al. Chemosensitivity of lymphocytes
from patients with B-cell chronic lymphocytic leukemia to chlorambucil,
fludarabine, and camptothecin analogs. Blood 1994; 84: 3440-3446.
60. Bosanquet AG. The DiSC assay - 10 years and 2000 tests further on.
In: Kaspers GJL, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP, eds.
Drug Resistance in Leukemia and Lymphoma. Chur: Harwood Academic Publishers,
1993: 373-383.
61. Asanuma F, Yamada Y, Kawamura E, et al. [Comparison between clinical
response and in vitro chemosensitivity of solid tumors in the succinic
dehydrogenase inhibition test]. Gan To Kagaku Ryoho 1992; 19: 95-101.
62. Furukawa T, Kubota T, Hoffman RM. Clinical applications of the histoculture
drug response assay. Clin Cancer Res 1995; 1: 305-311.
63. Imai S. Comparative study of histopathological effects of preoperative
chemotherapy using UFT and in vitro MTT assay of colonoscopy specimens
from patients with colorectal cancer. Jpn J Cancer Chemother 1999; 26:
1289-1293.
64. Furukawa T, Kubota T, Suto A, et al. Clinical usefulness of chemosensitivity
testing using the MTT assay. J Surg Oncol 1991; 48: 188-193.
65. Meitner PA. The fluorescent cytoprint assay: A new approach to in vitro
chemosensitivity testing. Oncology (U S A ) 1991; 5: 75-82.
66. Smit EF, De Vries EGE, Meijer C, Mulder NH, Postmus PE. Limitations
of the fast green assay for chemosensitivity testing in human lung cancer.
Chest 1991; 100: 1358-1363.
67. Wilbur DW, Camacho ES, Hilliard DA, Dill PL, Weisenthal LM. Chemotherapy
of non-small cell lung carcinoma guided by an in vitro drug resistance
assay measuring total tumour cell kill. Br J Cancer 1992; 65: 27-32.
68. Carstensen H, Tholander B. Chemosensitivity of ovarian carcinoma: In
vitro/in vivo correlations using the dye exclusion assay of Weisenthal
(meeting abstract). Proceedings: 3rd European Conference on Clinical Oncology
1985; Stockholm: p. 206-206. Click here to view abstract.
69. Ng TY, Ngan HYS, Cheng DKL, Wong LC. Clinical applicability of
the ATP cell viability assay as a predictor of chemoresponse in platinum-resistant
epithelial ovarian cancer using nonsurgical tumor cell samples. Gynec Oncol
2000; 76: 405-408.
70. Konecny G, Crohns C, Pegram M, et al. . Correlation of drug response
with the ATP tumorchemosensitivity assay in priamry FIGO stage III ovarian
cancer. Gynecol Oncol 2000; 77: 258-263.
71. Ohie S, Udagawa Y, Kozu A, et al. Cisplatin sensitivity of ovarian
cancer in the histoculture drug response assay correlates to clinical response
to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
Anticancer Res 2000; 20: 2049-2054.
72. Sargent J, Elgie A, Taylor CG, Wilson J, Alton P, Hill JG. The identification
of drug resistance in ovarian cancer and breast cancer: application of
the MTT assay. In: Koechli OR, Sevin B-U, Haller U, eds. Chemosensitivity
testing in gynecologic malignancies and breast cancer. Basel: Karger, 1994:
64-75.
73. Sevin B-U, Perras JP, Averette HE, Donato DM, Penalver M. Chemosensitivity
testing in ovarian cancer. Cancer 1993; 71(Suppl): 1613-1620.
74. Sevin B-U, Perras JP, Koechli OR. Current status and future directions
of chemosensitivity testing. In: Koechli OR, Sevin B-U, Haller U, eds.
Chemosensitivity testing in gynecologic malignancies and breast cancer.
Basel: Karger, 1994: 179-194.
75. Taylor CG, Sargent JM, Elgie AW, et al. . The clinical relevance of
chemosensitivity testing in ovarian cancer. Cancer Detect Prev 1998; 22:
305-312.
76. Weisenthal LM. Predictive assays for drug and radiation resistance.
In: Masters JM, ed. Cancer in Primary Culture: A Handbook (Developments
in Oncology, V. 64). Dordrecht, The Netherlands: Kluwer Acad Publishers,
1991: 103-147.
77. Schrek R. Differences between responsive and intractable chronic lymphocytic
leukemia. Med Hypotheses 1990; 31: 81-82.
78. Schrek R, Dolowy WC, Ammeraal RN. L-asparaginase: toxicity to normal
and leukemic human lymphocytes. Science 1967; 155: 329-330.
79. Schrek R. Sensitivity of normal and leukemic lymphocytes and leukemic
myeloblasts to heat. J Natl Cancer Inst 1966; 37: 649-654.
80. Schrek R, Leithold SL, Friedman IA, Best WR. Clinical evaluation of
an in vitro test for radiosensitivity of leukemic lymphocytes. Blood 1962;
20: 432-442.
81. Schrek R. A method for counting the viable cells in normal and in malignant
cell suspensions. Am J Cancer 1936; 28: 389-392.
82. Durkin WJ, Ghanta VK, Balch CM, Davis DW, Hiramoto RN. A methodological
approach to the prediction of anticancer drug effect in humans. Cancer
Res 1979; 39: 402-407.
83. Weisenthal LM, Marsden JA. A novel dye exclusion assay for predicting
response to cancer chemotherapy. Proc Am Assoc Cancer Res 1981; 22: 155.(Abstract)
84. Weisenthal LM, Marsden JA, Malefatto J, Dill PL. Predicting response
to cancer chemotherapy with a novel dye exclusion assay. Proceedings of
XIIth International Congress of Chemotherapy,Florence,Italy 1981; (Abstract)
85. Bosanquet AG, Bird MC, Price WJ, Gilby ED. An assessment of a short-term
tumour chemosensitivity assay in chronic lymphocytic leukaemia. Br J Cancer
1983; 47: 781-789.
86. Nygren P, Fridborg H, Csoka K, et al. Detection of tumor-specific cytotoxic
drug activity in vitro using the fluorometric microculture cytotoxicity
assay and primary cultures of tumor cells from patients. Int J Cancer 1994;
56: 715-720.
87. Pieters R, Loonen AH, Huismans DR, et al. In vitro drug sensitivity
of cells from children with leukemia using the MTT assay with improved
culture conditions. Blood 1990; 76: 2327-2336.
88. Pieters R, Kaspers GJ, Klumper E, Veerman AJ. Clinical relevance of
in vitro drug resistance testing in childhood acute lymphoblastic leukemia:
the state of the art. Med Pediatr Oncol 1994; 22: 299-308.
89. Kaspers GJ, Kardos G, Pieters R, et al. Different cellular drug resistance
profiles in childhood lymphoblastic and non-lymphoblastic leukemia: a preliminary
report. Leukemia 1994; 8: 1224-1229.
90. Klumper E, Pieters R, Veerman AJ, et al. In vitro cellular drug resistance
in children with relapsed/refractory acute lymphoblastic leukemia. Blood
1995; 86: 3861-3868.
91. Hongo T, Fujii Y. In vitro chemosensitivity of lymphoblasts at relapse
in childhood leukemia using the MTT assay. Int J Hematol 1991; 54: 219-230.
92. Nagourney RA, Groncy PK, Oseas RS, Finklestein JZ, Weisenthal LM. Glucocorticoid
sensitivity assessed in vitro: a new prognostic factor for relapse in childhood
acute lymphoblastic leukemia (meeting abstract). Proc Am Soc Clin Oncol
1988; 7: A715.
93. Nagourney RA, Weisenthal LM. Dexamethasone-induced cell death in primary
cultures of childhood A.L.L. predict survival: a prospective trial with
13 year follow-up. Leukemia 1995; 9: 531.
94. Kaspers GJL, Pieters R, Van Zantwijk CH, et al. In vitro drug sensitivity
of normal peripheral blood lymphocytes and childhood leukaemic cells from
bone marrow and peripheral blood. Br J Cancer 1991; 64: 469-474.
95. Pieters R, Huismans DR, Loonen AH, et al. Relation of cellular drug
resistance to long-term clinical outcome in childhood acute lymphoblastic
leukaemia. Lancet 1991; 338: 399-403.
96. Pieters R, Kaspers GJL, Van Wering ER, et al. Cellular drug resistance
profiles that might explain the prognostic value of immunophenotype and
age in childhood acute lymphoblastic leukemia. Leukemia 1993; 7: 392-397.
97. Veerman AJ. Cellular drug resistance in childhood leukemia. Ann Hematol
1994; 69: 31-34.
98. Kaspers GJL, Smets LA, Pieters R, Van Zantwijk CH, Van Wering ER, Veerman
AJP. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia
may be explained by sensitivity to antimetabolites and other drugs: results
of an in vitro study. Blood 1995; 85: 751-756. 99. Styczynski J, Pieters
R, Huismans DR, Schuurhuis GJ, Wysocki M, Veerman AJ. In vitro drug resistance
profiles of adult versus childhood acute lymphoblastic leukaemia. Br J
Haematol 2000; 110: 813-818.
100. Janka-Schaub GE, Harms DO, den Boer ML, Veerman AJ, Pieters R. In
vitro drug resistance as independent prognostic factor in the study COALL-O5-92
Treatment of childhood acute lymphoblastic leukemia; two- tiered classification
of treatments based on accepted risk criteria and drug sensitivity profiles
in study COALL-06-97. Klin Padiatr 1999; 211: 233-238.
101. Pieters R, den Boer ML, Durian M, et al. Relation between age, immunophenotype
and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications
for treatment of infants. Leukemia 1998; 12: 1344-1348.
102. Kaspers GJ, Pieters R, Van Zantwijk CH, Van Wering ER, Van der Does-van
den Berg A, Veerman AJ. Prednisolone resistance in childhood acute lymphoblastic
leukemia: vitro-vivo correlations and cross-resistance to other drugs.
Blood 1998; 92: 259-266.
103. Kaspers GJ, Veerman AJ, Pieters R, et al. In vitro cellular drug resistance
and prognosis in newly diagnosed childhood acute lymphoblastic leukemia.
Blood 1997; 90: 2723-2729.
104. Klumper E, Ossenkoppele GJ, Pieters R, et al. In vitro resistance
to cytosine arabinoside, not to daunorubicin, is associated with the risk
of relapse in de novo acute myeloid leukaemia. Br J Haematol 1996; 93:
903-910.
105. Zwaan CM, Kaspers GJ, Pieters R, et al. Cellular drug resistance profiles
in childhood acute myeloid leukemia: differences between FAB types and
comparison with acute lymphoblastic leukemia. Blood 2000; 96: 2879-2886.
106. Nygren P, Kristensen J, Jonsson B, et al. Feasibility of the fluorometric
microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing
of tumor cells from patients with acute lymphoblastic leukemia. Leukemia
1992; 6: 1121-1128.
107. Kristensen J, Jonsson B, Sundstrom C, Nygren P, Larsson R. In vitro
analysis of drug resistance in tumor cells from patients with acute myelocytic
leukemia. Med Oncol Tumor Pharmacother 1992; 9: 1-9.
108. Larsson R, Nygren P. Prediction of individual patient response to
chemotherapy by the fluorometric microculture cytotoxicity assay (FMCA)
using drug specific cut-off limits and a Bayesian model. Anticancer Res
1993; 13: 1825-1829.
109. Kristensen J, Jonsson B, Sundstrom C, Nygren P, Larsson R. In vitro
analysis of drug resistance in tumor cells from patients with acute myelocytic
leukemia [published erratum appears in Med Oncol Tumor Pharmacother 1992;9(3):157].
Med Oncol Tumor Pharmacother 1992; 9: 65-74.
110. Larsson R, Fridborg H, Kristensen J, Sundstrom C, Nygren P. In vitro
testing of chemotherapeutic drug combinations in acute myelocytic leukaemia
using the fluorometric microculture cytotoxicity assay (FMCA). Br J Cancer
1993; 67: 969-974.
111. Staib P, Schinkothe T, Henrichs T, et al. In vitro drug resistance
testing may provide an independent prognostic factor for adult patients
with AML. Proc Am Soc Hematol (ASH) Annual Meeting 1999; Abs # 269: (Abstract)
112. Hwang WS, Chen LM, Huang SH, Wang CC, Tseng MT. Prediction of chemotherapy
response in human leukemia using in vitro chemosensitivity test. Leuk Res
1993; 17: 685-688.
113. Mollgard L, Tidefelt U, Sundman-Engberg B, Lofgren C, Paul C. In vitro
chemosensitivity testing in acute non lymphocytic leukemia using the bioluminescence
ATP assay. Leuk Res 2000; 24: 445-452.
114. Bird MC, Bosanquet AG, Forskitt S, Gilby ED. Long-term comparison
of results of a drug sensitivity assay in vitro with patient response in
lymphatic neoplasms. Cancer 1988; 61: 1104-1109.
115. Bosanquet AG. Correlations between therapeutic response of leukaemias
and in-vitro drug-sensitivity assay. Lancet 1991; 337: 711-714.
116. Bosanquet AG, Johnson SA, Richards SM. Prognosis for fludarabine therapy
of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC
assay. Br J Haematol 1999; 106: 71-77.
117. Bosanquet AG, McCann SR, Crotty GM, Mills MJ, Catovsky D. Methylprednisolone
in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness
of treatment suggested by DISC assay. Acta Haematologica 1995; 93: 73-79.
118. Thornton PD, Hamblin M, Treleaven JG, Matutes E, Lakhani AK, Catovsky
D. High dose methyl prednisolone in refractory chronic lymphocytic leukaemia.
Leuk Lymphoma 1999; 34: 167-170.
119. Catchpoole DR, Stewart BW. Etoposide-induced cytotoxicity in two human
T-cell leukemic lines: delayed loss of membrane permeability rather than
DNA fragmentation as an indicator of programmed cell death. Cancer Res
1993; 53: 4287-4296.
120. Larsson R, Nygren P. Laboratory prediction of clinical chemotherapeutic
drug resistance: a working model exemplified by acute leukaemia. Eur J
Cancer 1993; 29A: 1208-1212.
121. Fridborg H, Jonsson E, Nygren P, Larsson R. Relationship between diagnosis-specific
activity of cytotoxic drugs in fresh human tumour cells ex vivo and in
the clinic. Eur J Cancer 1999; 35: 424-432.
122. Mason JM, Drummond MF, Bosanquet AG, Sheldon TA. The DiSC assay. A
cost-effective guide to treatment for chronic lymphocytic leukemia? Int
J Technol Assess Health Care 1999; 15: 173-184.
123. Pieters R, Huismans DR, Loonen AH, et al. Relation of cellular drug
resistance to long-term clinical outcome in childhood acute lymphoblastic
leukaemia. Lancet 1991; 338: 399-403.
124. Kaspers GJ, Veerman AJ, Pieters R, Van Zantwijk CH, Van Wering ER,
Van der Does-van den Berg A. In vitro drug resistance profile: strongest
prognostic factor in childhood acute lymphoblastic leukemia (ALL) (meeting
abstract). Blood 1994; 84: 516a.
125. Veerman AJ, Kaspers GJ, Pieters R. Cellular drug resistance in childhood
leukemia. Ann Hematol 1994; 69 Suppl 1: S31-S34.
126. Klumper E, Ossenkoppele GJ, Pieters R, et al. In vitro resistance
to cytosine arabinoside, not to daunorubicin, is associated with the risk
of relapse in de novo acute myeloid leukaemia. Br J Haematol 1996; 93:
903-910.
127. Norgaard JM, Langkjer ST, Palshof T, Pedersen B, Hokland P. Pretreatment
leukaemia cell drug resistance is correlated to clinical outcome in acute
myeloid leukaemia. Eur J Haematol 2001; 66: 160-167.
128. Kobayashi H, Man S, Graham CH, Kapitain SJ, Teicher BA, Kerbel RS.
Acquired multicellular-mediated resistance to alkylating agents in cancer.
Proc Natl Acad Sci U S A 1993; 90: 3294-3298.
129. Kerbel RS. Impact of multicellular resistance on the survival of solid
tumors, including micrometastases. Invasion Metastasis 1994; 14: 50-60.
130. Desoize B, Gimonet D, Jardiller JC. Cell culture as spheroids: an
approach to multicellular resistance. Anticancer Res 1998; 18: 4147-4158.
131. Desoize B, Jardillier J. Multicellular resistance: a paradigm for
clinical resistance? Crit Rev Oncol Hematol 2000; 36: 193-207.
132. Shaw GL, Gazdar AF, Phelps R, et al. Individualized chemotherapy for
patients with non-small cell lung cancer determined by prospective identification
of neuroendocrine markers and in vitro drug sensitivity testing. Cancer
Res 1993; 53: 5181-5187.
133. Furukawa T, Kubota T, Hoffman RM. Clinical applications of the histoculture
drug response assay. Clin Cancer Res 1995; 1: 305-311.
134. Baba H, Takeuchi H, Inutsuka S, et al. Clinical value of SDI test
for predicting effect of postoperative chemotherapy for patients with gastric
cancer. Semin Surg Oncol 1994; 10: 140-144. 135. Markman M. Chemosensitivity
and chemoresistance assays: are they clinically relevant? J Cancer Res
Clin Oncol 1995; 121: 441-442.
136. Suto A, Kubota T, Shimoyama Y, Ishibiki K, Abe O. MTT assay with reference
to the clinical effect of chemotherapy. J Surg Oncol 1989; 42: 28-32.
137. Saikawa Y, Kubota T, Furukawa T, et al. Single-cell suspension assay
with an MTT end point is useful for evaluating the optimal adjuvant chemotherapy
for advanced gastric cancer. Jpn J Cancer Res 1994; 85: 762-765.
138. Kurihara N, Kubota T, Furukawa T, et al. Chemosensitivity testing
of primary tumor cells from gastric cancer patients with liver metastasis
can identify effective antitumor drugs. Anticancer Res 1999; 19: 5155-5158.
139. Abe S, Kubota T, Matsuzaki SW, et al. Chemosensitivity test is useful
in evaluating the appropriate adjuvant cancer chemotherapy for stage III
non-scirrhous and scirrhous gastric cancers. Anticancer Res 1999; 19: 4581-4586.
140. Fujita K, Kubota T, Matsuzaki SW, et al. Further evidence for the
value of the chemosensitivity test in deciding appropriate chemotherapy
for advanced gastric cancer. Anticancer Res 1998; 18: 1973-1978.
141. Yamaue H, Tanimura H, Tsunoda T, et al. Chemosensitivity testing with
highly purified fresh human tumour cells with the MTT colorimetric assay.
Eur J Cancer 1991; 27: 1258-1263.
142. Yamaue H, Tanimura H, Noguchi K, et al. Chemosensitivity testing of
fresh human gastric cancer with highly purified tumour cells using the
MTT assay. Br J Cancer 1992; 66: 794-799.
143. Yamaue H, Tanimura H, Nakamori M, et al. Clinical evaluation of chemosensitivity
testing for patients with colorectal cancer using MTT assay. Dis Colon
Rectum 1996; 39: 416-422.
144. Kimura H, Yonemura Y, Ohyama S, et al. The succinate dehydrogenase
inhibition test for evaluating biopsy specimens and resected tumors of
advanced gastric cancer. Surg Today 1992; 22: 508-511.
145. Vescio RA, Redfern CH, Nelson TJ, Ugoretz S, Stern PH, Hoffman RM.
In vivo-like drug responses of human tumors growing in three-dimensional
gel-supported primary culture. Proc Natl Acad Sci U S A 1987; 84: 5029-5033.
146. Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding
to 5-fluorouracil have low gene expression levels of dihydropyrimidine
dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin
Cancer Res 2000; 6: 1322-1327.
147. Konecny G, Crohns C, Pegram M, et al. Correlation of drug response
with the ATP tumor chemosensitivity assay in primary FIGO stage III ovarian
cancer. Gynecol Oncol 2000; 77: 258-263.
148. Kurbacher CM, Cree IA, Bruckner HW, et al. Use of an ex vivo ATP luminescence
assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs
1998; 9: 51-57.
149. Cortazar P, Johnson BE. Review of the efficacy of individualized chemotherapy
selected by in vitro drug sensitivity testing for patients with cancer.
J Clin Oncol 1999; 17: 1625-1631.
150. Link KH, Kornmann M, Butzer U, et al. Thymidylate synthase quantitation
and in vitro chemosensitivity testing predicts responses and survival of
patients with isolated nonresectable liver tumors receiving hepatic arterial
infusion chemotherapy. Cancer 2000; 89: 288-296.
151. Lenz HJ, Leichman CG, Danenberg KD, et al. Thymidylate synthase mRNA
level in adenocarcinoma of the stomach: a predictor for primary tumor response
and overall survival. J Clin Oncol 1996; 14: 176-182.
152. McNeil C. Using HER2 to choose chemotherapy in breast cancer: is it
ready for the clinic? J Natl Cancer Inst 1999; 91: 110-112.
153. Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy
for invasive breast cancer: National Surgical Adjuvant Breast and Bowel
Project Protocol B-15. J Natl Cancer Inst 2000; 92: 1991-1998.
154. Nelson NJ. Can HER2 status predict response to cancer therapy? J Natl
Cancer Inst 2000; 92: 366-367.
155. Aabo K, Adams M, Adnitt P, et al. Chemotherapy in advanced ovarian
cancer: four systematic meta-analyses of individual patient data from 37
randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer
1998; 78: 1479-1487.
156. Colombo N, ICON Collaborators MRC Clinical Trials Unit . Randomized
trial of paclitaxel and carboplatin versus a control arm of carboplatin
or CAP (cyclophosphamide, doxorubicin, and cisplatin): The Third International
Collaborative Ovarian Neoplasm Study (ICON3). Proc Annu Meet Am Soc Clin
Oncol 2000; Abs # 1500: (Abstract)
157. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of
cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients
with suboptimal stage III or IV ovarian cancer: a gynecologic oncology
group study. J Clin Oncol 2000; 18: 106-115.
158. Strauss E. Pretesting Tumors. Sci Am 1999; 280: 19-20.
159. Stein R. Official U.S. Government transcript of Health Care Finance
Administration technology assessment committee meeting on Human Tumor Assay
Systems, Baltimore, MD, November 15, 1999, Volume 1, pp. 92-99. Available
on the internet: http://cms.hhs.gov/coverage/8b1-h1.asp
Backup link: http://weisenthal.org/hcfa_1.htm
160. Nalick R. Official U.S. Government transcript of Health Care Finance
Administration technology assessment meeting on Human Tumor Assay Systems,
Baltimore, MD, Nov. 15, 1999, Volume 1, pp. 106-107. Available on the internet:
http://cms.hhs.gov/coverage/8b1-h1.asp
Backup link:http://weisenthal.org/hcfa_1.htm
161. Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS. Gemcitabine
plus cisplatin repeating doublet therapy in previously treated, relapsed
breast cancer patients. J Clin Oncol 2000; 18: 2245-2249.
162. Weisenthal LM. Antineoplastic drug screening belongs in the laboratory,
not in the clinic [editorial]. J Natl Cancer Inst 1992; 84: 466-469.
163. Taylor CG, Sargent JM, Elgie AW, Williamson CJ, Lewandowicz GM, Chappatte
O, and Hill JG. Chemosensitivity testing predicts survival in ovarian cancer.
Eur J Gynaecol Oncol 2001; 22:278-82 Click here
to view abstract
Return to HTAJ Home Page
Return to Title/Abstract/Chapter Table of Contents
Return to Chapter 7: Editorial Conclusions